The transaction represents the largest equity transaction in Taiwan since 2005, and the largest GDR issuance ever completed in Taiwan's capital markets.
The optical module producer has made a secondary listing on the main board of the Hong Kong Stock Exchange, raising approximately $7bn; the city has already raised more so far this year on the HKEX than across 2025.
Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.
CEO Darren Wang described the process to FA as “difficult” and said that reaching out to more US-based private investors, while expanding globally, is the next step.